Plain-English translation of NCT06225310 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination of three medications for people with multiple myeloma that has come back or stopped responding to previous treatments. The main drug being tested is , which works by trapping tumor-fighting proteins inside cancer cells so they can't survive. You would take this medication along with two other drugs — and a steroid called — to see if the combination works better than any single drug alone.
Multiple myeloma is a blood cancer that often comes back even after successful treatment, and it can become resistant to standard therapies. Doctors hope that combining these three medications — which work in different ways to fight cancer cells — might offer a better option for patients whose cancer has stopped responding to other treatments.
You likely qualify if…
You likely don't qualify if…
You would take three oral medications on a schedule: once per week, twice daily for 28 days, and every other day. The trial uses a 'dose escalation' approach, meaning the earliest participants start at lower doses and later participants may receive higher doses to find the safest and most effective combination. You would have regular clinic visits and blood tests to monitor how the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States